[약업신문]Genexine exports 1.2 trillion won worth of technology for’GX-I’ to KG BIO

Genexine (CEO Seong Young-cheol) announced that it has transferred the technology of GX-I7 (substance name efineptakin alfa), which is being developed as an immune anticancer drug, to’KG BIO’ in Indonesia, a subsidiary of PT Kalbe Farma, the largest pharmaceutical company in Southeast Asia.

This technology export was granted to ASEAN countries and regions such as the Middle East, Australia, New Zealand, India, and Africa with the right to use GX-I7, with a down payment of 27 million dollars (about 30 billion won). In addition, it is worth up to $1.1 billion (about 1.2 trillion won), including sales milestones following future clinical progress, product approval, and commercialization. There is no obligation to return the down payment and milestones. Separately, when sales of GX-I7 are generated in the contracted area, 10% of the sales are paid as royalties.

Genexine CEO Seong Young-cheol said, “This technology transfer has once again recognized the value of GX-I7, a long-acting interleukin-7 formulation, a T cell amplifying agent.” “By actively cooperating with global partners including KG BIO, GX-I7 We will develop it as a new blockbuster drug that is recognized in the global market.”

KG BIO plans to apply for emergency use approval after the introduction of the technology from Genexin this time, if the efficacy of the treatment in phase 2 clinical trials for corona treatment currently in progress in Indonesia is proven.

In addition, the company is planning to conduct various clinical trials with HLX10, an immuno-oncology drug (anti-PD1) introduced in 2019 from Henlius (2696 HK), a subsidiary of Fosun Pharma, a leading Chinese pharmaceutical company.

This will not only confirm the value of GX-I7 as an anticancer drug, but also expand the target market to India, Oceania, the Middle East, and Africa by utilizing the strong sales network of the parent company Kalbe to grow it into a globally recognized anticancer drug pipeline to be.

GX-I7 is proving its value as an immune anticancer drug through various single or combination clinical trials targeting a number of carcinomas.

In particular, in the interim results of phase 1b/2 clinical trials in combination with Kitruda, an immune checkpoint inhibitor last year, the objective response rate (ORR) was increased by more than 5 times compared to Kitruda alone treatment, and it is scheduled to be used in combination with Roche’s Avastin. .

In addition, I-MAB biopharma (Nasdaq: IMAB), which received the technology transfer of GX-I7 from Genexine to the Chinese region, is under the product name TJ-107 and proceeds with a phase 2 clinical trial of malignant glioblastoma (GBM). Are doing.

In addition, Neoimmuntech (NIT), which received the technology transfer of GX-I7 to the Americas and Europe, is a product named NT-I7, and various anticancer drugs such as Roche’s Ticentric, Merck (MSD) Kitruda, BMS Opdivo, and Novartis Kimria. A combination clinical trial with